NHS wins landmark High Court battle with two major drug firms
A judge rejected an action brought by Bayer and Novartis against 12 NHS clinical commissioning groups in north England relating to Avastin, an age-related macular degeneration drug. (Source: the Mail online | Health)
Source: the Mail online | Health - September 21, 2018 Category: Consumer Health News Source Type: news

Avastin/Lucentis/Eylea ruling good news for patients, says RPS
Responding to news that the NHS will allow Avastin to be prescribed for age related wet macular degeneration, RPS President Ash Soni said:“This is a landmark ruling and good news for patients (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - September 21, 2018 Category: Drugs & Pharmacology Source Type: news

Surgery for Mesothelioma No Longer Recommended in UK
Aggressive surgery for the treatment of malignant pleural mesothelioma (MPM) — unless part of a clinical trial — is no longer being recommended in the United Kingdom. The British Thoracic Society recently published its Mesothelioma Management Guidelines for 2018 and removed surgery from its recommendations. The belief was that potential harm was not worth the risk. The backtrack on surgery included the extrapleural pneumonectomy (EPP), the extended pleurectomy and decortication (P/D) and the partial pleurectomy (PP) — all of which are being done at cancer centers in the United States. “Surgery is a ...
Source: Asbestos and Mesothelioma News - September 11, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Roche Provides Update on Supplemental Biologics License Application (sBLA) for TECENTRIQ in First-line Metastatic Non-Squamous NSCLC
On September 05 2018, Roche was notified by the U.S. Food and Drug Administration (FDA) that the review period for the supplemental Biologics License Application (sBLA) for TECENTRIQ ® (atezolizumab) in combination with Avastin® (bevacizumab), carboplatin and paclitaxel for the initial treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) has been extended by three months. (Source: Roche Investor Update)
Source: Roche Investor Update - September 6, 2018 Category: Pharmaceuticals Source Type: news

Should Colorectal Tumor Sidedness Affect Chemotherapy Choice? Should Colorectal Tumor Sidedness Affect Chemotherapy Choice?
Dr David Kerr discusses a recent case in the context of data supporting triplet chemotherapy plus bevacizumab in colorectal cancer.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Adjuvant Bevacizumab Fails to Help in High-Risk Breast Cancer
The addition of bevacizumab to adjuvant chemotherapy regimens does not improve survival in women with high-risk breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - August 1, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Report: IBM Watson delivered ‘unsafe and inaccurate’ cancer recommendations
Internal documents from IBM Watson Health (NYSE:IBM) indicate that the company’s Watson for Oncology product often returns “multiple examples of unsafe and incorrect treatment recommendations,” according to a new report from STAT News. The documents come from slides presented last year by IBM Watson Health’s deputy chief health officer, according to the report, and include feedback from customers that indicated the product is “often inaccurate” and that its recommendations bring to light “serious questions about the process for building content and the underlying technology.&r...
Source: Mass Device - July 25, 2018 Category: Medical Devices Authors: Fink Densford Tags: Oncology Software / IT IBM Watson Health Source Type: news

Can Bevacizumab Be Recommended in High-Risk Melanoma?
Treatment of high-risk melanoma with adjuvant bevacizumab following resection improves disease-free survival over standard observation, but not overall survival. (Source: CancerNetwork)
Source: CancerNetwork - July 24, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

FDA grants Breakthrough Therapy Designation for Roche's Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) as an initial (first-line) treatment for people with advanced or metastatic hepatocellular carcinoma (HCC), the most common form of liver cancer. (Source: World Pharma News)
Source: World Pharma News - July 19, 2018 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

FDA grants Breakthrough Therapy Designation for Roche ’s Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)
Roche today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as an initial (first-line) treatment for people with advanced or metastatic hepatocellular carcinoma (HCC), the most common form of liver cancer. (Source: Roche Media News)
Source: Roche Media News - July 18, 2018 Category: Pharmaceuticals Source Type: news

FDA grants Breakthrough Therapy Designation for Roche ’s Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)
Roche today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as an initial (first-line) treatment for people with advanced or metastatic hepatocellular carcinoma (HCC), the most common form of liver cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - July 18, 2018 Category: Pharmaceuticals Source Type: news

Bevacizumab Rechallenge Benefit in Recurrent Ovarian Cancer?
New data suggest adding bevacizumab to chemotherapy may prolong PFS in patients with recurrent ovarian cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 19, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

FDA approves Roche ’s Avastin (bevacizumab) plus chemotherapy as a treatment for women with advanced ovarian cancer following initial surgery
Roche today announced that the US Food and Drug Administration (FDA) has approved Avastin ® (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin as a single agent, for the treatment of women with advanced (stage III or IV) ovarian cancer following initial surgical resection. (Source: Roche Media News)
Source: Roche Media News - June 13, 2018 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Avastin (bevacizumab) plus chemotherapy as a treatment for women with advanced ovarian cancer following initial surgery
Roche today announced that the US Food and Drug Administration (FDA) has approved Avastin ® (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin as a single agent, for the treatment of women with advanced (stage III or IV) ovarian cancer following initial surgical resection. (Source: Roche Investor Update)
Source: Roche Investor Update - June 13, 2018 Category: Pharmaceuticals Source Type: news

FDA Approves Genentech ’s Avastin (bevacizumab) Plus Chemotherapy as a Treatment for Women With Advanced Ovarian Cancer Following Initial Surgery
South San Francisco, CA -- June 13, 2018 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin ® (bevacizumab) in combination with chemotherapy... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 13, 2018 Category: Drugs & Pharmacology Source Type: news

Nintedanib ‘ Superior ’ to Bevacizumab for Mesothelioma Treatment
Researchers in Austria, Germany and Hungary have added to the growing belief that the anti-cancer drug nintedanib may soon become a significant part of standard-of-care treatment for malignant pleural mesothelioma. In their study published recently in Clinical Cancer Research, nintedanib demonstrated an ability to inhibit the growth and the migration of mesothelioma tumor cells effectively in animal models. “This is a step in the right direction, another part of the evolutionary process of treatment advancements with this difficult disease,” Dr. Balazs Hegedus, department of thoracic surgery, University of Dui...
Source: Asbestos and Mesothelioma News - June 11, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Second-Line Irinotecan/Cetuximab/Ramucirumab Combo Ups PFS in Advanced CRC
John SchieszerJun 6, 2018A combination of irinotecan, cetuximab, and ramucirumab may boost PFS in advanced CRC, when given after failure of oxaliplatin-and-bevacizumab –based therapy. (Source: CancerNetwork)
Source: CancerNetwork - June 7, 2018 Category: Cancer & Oncology Authors: A Source Type: news

PFS Rises in Ovarian Ca with Repeat Bevacizumab
(MedPage Today) -- Magnitude of benefit similar to first-line therapy (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 6, 2018 Category: Hematology Source Type: news

Atezolizumab Increases Progression-free Survival in Lung Cancer Patients – Study Atezolizumab Increases Progression-free Survival in Lung Cancer Patients – Study
Adding atezolizumab to a combination of bevacizumab, carboplatin and paclitaxel gives patients with metastatic nonsquamous non-small-cell lung cancer better odds of progression-free and overall survival, a new study of 692 patients with wild-type disease has concluded.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 5, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Patients Report Better RCC Outcomes for Atezolizumab + Bevacizumab
Bryant FurlowJun 4, 2018Patients treated for RCC with atezolizumab plus bevacizumab reported fewer impacts to daily function and quality of life than those on sunitinib. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Bevacizumab most cost-effective treatment for AMD
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2018 Category: Drugs & Pharmacology Source Type: news

Cancer nurse, 43, is overcoming the disease after strangers donated for a drug not on the NHS
Last March, mother-of-two Laura Harris, 43, from Devon, who has advanced bowel cancer, was given just three months to live unless she could raise £21,000 to be treated by the drug Bevacizumab. (Source: the Mail online | Health)
Source: the Mail online | Health - May 31, 2018 Category: Consumer Health News Source Type: news

mAbxience and Amneal Enter Into an Agreement for Bevacizumab Biosimilar in the United States
The agreement to bring a biosimilar of bevacizumab to the United States will improve patient access and affordability of this important oncology treatment MADRID, May 23, 2018 -- (Healthcare Sales & Marketing Network) -- mAbxience, a company specialize... Biopharmaceuticals, Generics, Licensing mAbxience, Insud Pharma Group, Amneal Pharmaceuticals, bevacizumab, biosimilar (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 23, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpower150 study showed Roche ’s Tecentriq and Avastin plus carboplatin and paclitaxel helped people with a specific type of metastatic lung cancer live significantly longer compared to Avastin plus carboplatin and paclitaxel
Roche today announced positive results from the Phase III IMpower150 study of Tecentriq ® (atezolizumab) and Avastin® (bevacizumab) plus carboplatin and paclitaxel (chemotherapy) for the initial (first-line) treatment of chemotherapy-naïve people with metastatic non-squamous non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - May 17, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpower150 study showed Roche ’s Tecentriq and Avastin plus carboplatin and paclitaxel helped people with a specific type of metastatic lung cancer live significantly longer compared to Avastin plus carboplatin and paclitaxel
Roche today announced positive results from the Phase III IMpower150 study of Tecentriq ® (atezolizumab) and Avastin® (bevacizumab) plus carboplatin and paclitaxel (chemotherapy) for the initial (first-line) treatment of chemotherapy-naïve people with metastatic non-squamous non-small cell lung cancer (NSCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - May 17, 2018 Category: Pharmaceuticals Source Type: news

Roche immunotherapy combination increases lung cancer survival - study
(Reuters) - Roche's immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tecentriq, according to interim results of a late stage trial released on Wednesday. (Source: Reuters: Health)
Source: Reuters: Health - May 16, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA grants priority review to Roche's cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ® (atezolizumab), in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC). (Source: World Pharma News)
Source: World Pharma News - May 8, 2018 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Roche's Tecentriq combo wins fast FDA review in race to catch rivals
ZURICH (Reuters) - Roche's immunotherapy combination that includes Tecentriq, Avastin and chemotherapy will get an accelerated review by U.S. regulators for use as an initial treatment of a common form of lung cancer, the Swiss drugmaker said on Monday. (Source: Reuters: Health)
Source: Reuters: Health - May 7, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Roche's Tecentriq combination to get speedy FDA review
ZURICH (Reuters) - Roche's immunotherapy combination that includes Tecentriq, Avastin and chemotherapy will get a speeded-up review by U.S. regulators for use in initial treatment of people with a common form of lung cancer, the Swiss drugmaker said on Monday. (Source: Reuters: Health)
Source: Reuters: Health - May 7, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA grants priority review to Roche ’s cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ® (atezolizumab), in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - May 7, 2018 Category: Pharmaceuticals Source Type: news

FDA grants priority review to Roche ’s cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ® (atezolizumab), in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - May 7, 2018 Category: Pharmaceuticals Source Type: news

FDA grants priority review to Roche ’s cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for TECENTRIQ® (atezolizumab), in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - May 7, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpower150 study showed Roche ’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin plus carboplatin and paclitaxel
Roche today announced that the Phase III IMpower150 study met its co-primary endpoint of overall survival (OS) at this interim analysis and showed that initial (first-line) treatment with the combination of TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) plus carboplatin and paclitaxel (chemotherapy) helped people with advanced non-squamous non-small cell lung cancer (NSCLC) live significantly longer compared with Avastin plus carboplatin and paclitaxel. (Source: Roche Media News)
Source: Roche Media News - March 26, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpower150 study showed Roche ’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin plus carboplatin and paclitaxel
Roche today announced that the Phase III IMpower150 study met its co-primary endpoint of overall survival (OS) at this interim analysis and showed that initial (first-line) treatment with the combination of TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) plus carboplatin and paclitaxel (chemotherapy) helped people with advanced non-squamous non-small cell lung cancer (NSCLC) live significantly longer compared with Avastin plus carboplatin and paclitaxel. (Source: Roche Investor Update)
Source: Roche Investor Update - March 26, 2018 Category: Pharmaceuticals Source Type: news

Cipla ties up with Roche to sell 2 cancer drugs in India
The pharma major will distribute Tocilizumab and Syndyma -- the second brand of Roche's cancer therapy bevacizumab -- in India. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 27, 2018 Category: Pharmaceuticals Source Type: news

Anti-VEGF Agents Improve Vision Despite Ongoing Diabetic Macular Edema Anti-VEGF Agents Improve Vision Despite Ongoing Diabetic Macular Edema
In patients with diabetic macular edema (DME), aflibercept and ranibizumab are more effective than bevacizumab in preventing disease persistence, but each drug can lead to substantial gains in vision, according to a post hoc analysis of a randomized trial.Reuters Health Information (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - February 14, 2018 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Two Anti-VEGF Agents Shine in DME Trial
(MedPage Today) -- Bevacizumab lags in three-way comparison (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - February 13, 2018 Category: Primary Care Source Type: news

Combo Bests Targeted Agent in mRCC
(MedPage Today) -- Improved PFS with first-line atezolizumab and bevacizumab pairing (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 7, 2018 Category: Hematology Source Type: news

Phase III IMmotion151 study showed Roche's TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer
Roche today announced results from the positive Phase III IMmotion151 study of TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) as a first-line treatment for advanced or metastatic renal cell carcinoma (mRCC). (Source: Roche Media News)
Source: Roche Media News - February 6, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMmotion151 study showed Roche's TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer
Roche today announced results from the positive Phase III IMmotion151 study of TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) as a first-line treatment for advanced or metastatic renal cell carcinoma (mRCC). (Source: Roche Investor Update)
Source: Roche Investor Update - February 6, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMmotion151 study showed Roche's TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer
Roche today announced results from the positive Phase III IMmotion151 study of TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) as a first-line treatment for advanced or metastatic renal cell carcinoma (mRCC). (Source: Roche Media News)
Source: Roche Media News - February 6, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMmotion151 study showed Roche's TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer
Roche today announced results from the positive Phase III IMmotion151 study of TECENTRIQ ® (atezolizumab) and Avastin® (bevacizumab) as a first-line treatment for advanced or metastatic renal cell carcinoma (mRCC). (Source: Roche Investor Update)
Source: Roche Investor Update - February 6, 2018 Category: Pharmaceuticals Source Type: news

Support for Upfront Immunotherapy in Advanced Renal Cell Cancer Support for Upfront Immunotherapy in Advanced Renal Cell Cancer
Atezolizumab plus bevacizumab improves progression-free survival with greater tolerability than standard sunitinib in advanced kidney cancer in a randomized controlled trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 5, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

IV Bevacizumab Effective for Severe HHT - Related Bleeding
Drop in RBC transfusion requirements, epistaxis severity in hereditary hemorrhagic telangiectasia (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 5, 2018 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pharmacy, Journal, Source Type: news

New and highly sensitive ELISA technique for bioanalysis of bevacizumab
(Bentham Science Publishers) Bevacizumab is an anti-growth factor vascular endothelial growth factor (VEGF) monoclonal antibody, it is the antiangiogenic agent at the most advanced stage of development in the treatment of NSCLC.This drug was selected because of its inter individual differences in clinical response, its therapeutic importance in the treatment of non-small cell lung cancer (NSCLC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 31, 2018 Category: International Medicine & Public Health Source Type: news

Bevacizumab dramatically improves severe hereditary hemorrhagic telangiectasia (HHT) associated bleeding
(Elsevier) Patients with hereditary hemorrhagic telangiectasia (HHT) with severe bleeding, who were treated with intravenous bevacizumab, reported a marked reduction in nose bleeds and gastrointestinal bleeding and were able to stop or considerably reduce blood transfusions, resulting in significantly improved quality of life. A new study published in Mayo Clinic Proceedings provides good quality evidence for the excellent safety profile and efficacy of intravenous bevacizumab in the management of these patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 29, 2018 Category: International Medicine & Public Health Source Type: news

No Survival Benefit with Bevacizumab Maintenance in CRC (CME/CE)
(MedPage Today) -- Monotherapy no better than observation after induction chemo (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - January 28, 2018 Category: Gastroenterology Source Type: news

No Benefit With Bevacizumab Maintenance Therapy for Metastatic CRC During Chemo-Free Intervals
Adding bevacizumab maintenance therapy failed to improve outcomes compared with no treatment when administered during chemotherapy-free intervals to patients with metastatic colorectal cancer after induction chemotherapy. (Source: CancerNetwork)
Source: CancerNetwork - January 25, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Colorectal Cancer Gastrointestinal Cancer News Source Type: news

European Commission Approves Amgen And Allergan's MVASI ® (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
Marketing Authorization Based on Global Development Program Showing MVASI is Highly Similar to Avastin® (Bevacizumab) First Biosimilar Bevacizumab Approved in the European Union THOUSAND OAKS, Calif., Jan. 18, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced that the European Commission (EC) has granted marketing authorization for MVASI® (biosimilar bevacizumab). MVASI is the first biosimilar bevacizumab approved by the EC and is approved for the treatment of certain types of cancers, including in combination with fluoropyrimidine-based chemotherapy for metastatic ...
Source: Amgen News Release - January 18, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news